Accéder au contenu
Merck

The costimulatory molecule CD226 signals through VAV1 to amplify TCR signals and promote IL-17 production by CD4+ T cells.

Science signaling (2018-07-12)
Guillaume Gaud, Romain Roncagalli, Karima Chaoui, Isabelle Bernard, Julien Familiades, Céline Colacios, Sahar Kassem, Bernard Monsarrat, Odile Burlet-Schiltz, Anne Gonzalez de Peredo, Bernard Malissen, Abdelhadi Saoudi
RÉSUMÉ

The activation of T cells requires the guanine nucleotide exchange factor VAV1. Using mice in which a tag for affinity purification was attached to endogenous VAV1 molecules, we analyzed by quantitative mass spectrometry the signaling complex that assembles around activated VAV1. Fifty VAV1-binding partners were identified, most of which had not been previously reported to participate in VAV1 signaling. Among these was CD226, a costimulatory molecule of immune cells. Engagement of CD226 induced the tyrosine phosphorylation of VAV1 and synergized with T cell receptor (TCR) signals to specifically enhance the production of interleukin-17 (IL-17) by primary human CD4+ T cells. Moreover, co-engagement of the TCR and a risk variant of CD226 that is associated with autoimmunity (rs763361) further enhanced VAV1 activation and IL-17 production. Thus, our study reveals that a VAV1-based, synergistic cross-talk exists between the TCR and CD226 during both physiological and pathological T cell responses and provides a rational basis for targeting CD226 for the management of autoimmune diseases.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-LAT, Upstate®, from rabbit
Sigma-Aldrich
MISSION® esiRNA, targeting human VAV1